Literature DB >> 8249559

Evaluation of a new system for ventilatory administration of nitric oxide.

O Stenqvist1, B Kjelltoft, S Lundin.   

Abstract

A new system for delivery of nitric oxide (NO) to inspiratory gas consisting of two mass flow regulators and a soda-lime absorber for scavenging of nitrogen dioxide (NO2) is described. The system was evaluated using three different techniques for NO analysis (infrared, chemiluminescence and electro-chemical fuel cell technique). The electro-chemical fuel cell was less sensitive to humidity in the sample and is suitable for clinical routine use. The infrared analyser was very sensitive to humidity and the gas sample must be dried by silica gel, which absorbs NO2 and will cause falsely low NO2 values. NO2 was analysed with ultra-violet methodology. NO2 is highly toxic and the highest recommended occupational health and safety level for inhalation is 5 ppm. The highest values of NO2 in our system were detected before the absorber in the inspiratory limb of the breathing system, being 5 ppm at 100% oxygen and 100 ppm NO using "infant" respiratory settings (3 l/min in ventilation, frequency of 30/min). The corresponding value for "adult" respiratory settings (10 l/min in ventilation, frequency of 15/min) was 3.2 ppm. The absorber reduced these levels to well below 1 ppm. When clinically relevant levels of NO were used (20 ppm), no NO2 could be detected after the absorber, irrespective of oxygen concentration in the breathing gas. It was observed that gas cylinders with NO mixed in nitrogen may initially have a high NO2 concentration (around 12 ppm) and should be flushed thoroughly before use.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8249559     DOI: 10.1111/j.1399-6576.1993.tb03790.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  12 in total

1.  Pulmonary uptake and modes of administration of inhaled nitric oxide in mechanically-ventilated patients.

Authors: 
Journal:  Crit Care       Date:  1998       Impact factor: 9.097

2.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

3.  Inhaled nitric oxide delivery and monitoring.

Authors:  F J Montgomery; A D Berssenbrugge
Journal:  J Clin Monit Comput       Date:  1999-07       Impact factor: 2.502

4.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 5.  Delivery and monitoring of inhaled nitric oxide.

Authors:  J D Young; O J Dyar
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

6.  Response to nitric oxide inhalation in early acute lung injury.

Authors:  S Lundin; U N Westfelt; O Stenqvist; H Blomqvist; A Lindh; L Berggren; S Arvidsson; U Rudberg; C G Frostell
Journal:  Intensive Care Med       Date:  1996-08       Impact factor: 17.440

7.  Evaluation of a delivery system and monitors for ventilator administration of nitric oxide.

Authors:  Y K Choi; H Yukioka; T Yamada; M Hayashi; M Fujimori
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

8.  Comparison of two administration techniques of inhaled nitric oxide on nitrogen dioxide production.

Authors:  L Dubé; M Francoeur; E Troncy; R Carrier; G Blaise
Journal:  Can J Anaesth       Date:  1995-10       Impact factor: 5.063

9.  Conversion of inhaled nitric oxide to nitrate in man.

Authors:  U N Westfelt; G Benthin; S Lundin; O Stenqvist; A Wennmalm
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 10.  Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.

Authors:  Duncan J Macrae; David Field; Jean-Christophe Mercier; Jens Møller; Tom Stiris; Paolo Biban; Paul Cornick; Allan Goldman; Sylvia Göthberg; Lars E Gustafsson; Jürg Hammer; Per-Arne Lönnqvist; Manuel Sanchez-Luna; Gunnar Sedin; Nim Subhedar
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.